Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy

PURPOSE: The regimen including concurrent docetaxel, doxorubicin, and cyclophosphamide (TAC) has been categorized as an important risk factor for febrile neutropenia (FN). This comparative study examined the clinical impact of long-acting granulocyte colony-stimulating factor (G-CSF) (pegfilgrastim)...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Ye Won, Lim, Seung Taek, Gwak, HongKi, Park, Seon Young, Suh, Young Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604368/
https://www.ncbi.nlm.nih.gov/pubmed/33154827
http://dx.doi.org/10.4048/jbc.2020.23.e52

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604368/
https://www.ncbi.nlm.nih.gov/pubmed/33154827
http://dx.doi.org/10.4048/jbc.2020.23.e52

Ejemplares similares